Beth Ann Reedy

Evaluation Of Afuresertib, An Oral Pan-AKT Inhibitor, In Patients With Langerhans Cell Histiocytosis

R. Arceci, E. Jacobsen, C. Rodríguez-Galindo, 2013 .

3 Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancer

H. Gabra, L. Mileshkin, M. Hall, 2014 .

First‐in‐Human Study for a Selective Rearranged During Transfection Tyrosine Kinase Inhibitor, GSK3352589, to Investigate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers

A. Verticelli, K. Hacquoil, P. Gorycki, 2021, Clinical pharmacology in drug development.

First‐in‐Human Studies for a Selective RET Tyrosine Kinase Inhibitor, GSK3179106, to Investigate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers

A. Verticelli, K. Hacquoil, S. Shakib, 2018, Clinical pharmacology in drug development.

A phase IIa study of afuresertib, an oral pan‐AKT inhibitor, in patients with Langerhans cell histiocytosis

R. Arceci, M. Cornfeld, E. Jacobsen, 2017, Pediatric Blood & Cancer.

A Phase 1 Randomized, Placebo‐Controlled Trial With a Topical Inhibitor of Stearoyl‐Coenzyme A Desaturase 1 Under Occluded and Nonoccluded Conditions

S. Shakib, John Zhu, R. Brigandi, 2019, Clinical pharmacology in drug development.